April 23-25, 2024

The CRISPR Medicine Conference

Important Dates for the CRISPR Medicine Conference 2024

Before the Event:

  • September 1st, 2023: Registration & abstract submissions open
  • January 12th, 2024: Early bird registration deadline
  • January 24th, 2024: Abstract submission deadline
  • February 16th, 2024: Oral and poster notifications & final programme available
  • April 21st, 2024: Registration deadline
  • April 22nd, 2024: Abstract publication in the CRISPR Medicine News portal


  • April 22nd, 2024: Virtual event
  • April 23-25th, 2024: In-person event in Copenhagen, Denmark


The first CRISPR Medicine Conference will take place in Copenhagen, Denmark, on the 23-25th April 2024 (virtual event 22nd April). This event will bring European CRISPR research to the forefront, with 6 main tracks that cover the most important topics in the therapeutic gene-editing field: Tools, Delivery, Safety, Functional Genomics, Standards and Regulations, Pre-clinical Research and Clinical Trials.

This will be a hybrid event with a strong focus on in-person attendance and on-demand virtual content. The conference will include talks by reputable speakers from academia and industry, as well as several workshops focused on developing useful skills for a successful career in gene editing.

You can register to attend the event and submit an abstract directly through this website. Our separate in-person and virtual poster sessions will allow any type of attendee to present and discuss their research with their peers. The top-scoring abstracts will be presented as oral presentations and the authors will be interviewed by CRISPR Medicine News, which boasts an audience of over 20,000 readers per month.

Once you have registered, you will be able to explore the content and see the list of participants.

If you have any questions, please refer to our FAQ section or contact CRISPRMED24 staff at info@crisprmedicineconference.com

**CRISPRMED24 Newsletter - Sign up here**

Preliminary Program

Keynote Speaker

  • Luigi Naldini

    Luigi Naldini

    San Raffaele Telethon Institute for Gene Therapy and San Raffaele University, Milan, Italy

    Luigi Naldini, M.D., Ph.D., is Professor of Cell and Tissue Biology and of Gene and Cell Therapy at the San Raffaele University School of Medicine and Scientific Director of the San Raffaele Telethon Institute for Gene Therapy (Milan, Italy). He received his medical degree from the University of Turin (Italy) and his PhD from the University “La Sapienza” of Rome (Italy).

    For the past 25 years he has pioneered the development and application of lentiviral vectors for gene therapy, which have become one of the most widely used tools in biomedical research and, upon recently entering clinical testing, are providing a long-sought hope of cures for several currently untreatable and otherwise deadly human diseases. Throughout this time, he has continued to investigate new strategies to overcome the major hurdles to safe and effective gene transfer, bringing about innovative solutions that are not only being translated into new therapeutic strategies for genetic disease and cancer, but have also yielded novel insights into haematopoietic stem cell function, induction of immunological tolerance, and tumour angiogenesis.

    Professor Naldini's work has also contributed to advancing the use of artificial nucleases for targeted genome editing in cell- and gene therapy. To date, he has published over 290 scientific papers, and his SCOPUS Author h-index is 105. He is also co-founder of three innovative biotech start-up companies: Genenta (recently listed on Nasdaq), Epsilen Bio (now acquired by Chroma Medicine) and Genespire.

    Google Scholar ORCIID Lab Webpage


  • Ampliqon
  • Bayer
  • Benchling
  • BioSpring
  • Broken String Biosciences
  • CasCure
  • ChemoMetec
  • CountaGen
  • Full Circle Therapeutics
  • GenScript
  • iotaSciences
  • Samplix
  • SciLife Lab
  • Synthego
  • Vivlion
  • ZeClinics

Confirmed Speakers

  • Alessia Cavazza

    Alessia Cavazza

    University College London, United Kingdom

    Group Leader and Associate Professor in Gene Therapy at University College London's Great Ormond Street Institute of Child Health.

    Google Scholar ORCIID LinkedIn Lab Webpage

  • André Choulika

    André Choulika


    CEO at Cellectis.

    LinkedIn Company Webpage

  • André Cohnen

    André Cohnen

    Bayer AG

    Head of Genomic Medicine at Bayer.

    ORCIID LinkedIn Company Webpage

  • Andrew Bellinger

    Andrew Bellinger

    Verve Therapeutics

    CSO at Verve Therapeutics and Co-Founder at Corner Therapeutics

    LinkedIn Company Webpage

  • Angelo Lombardo

    Angelo Lombardo

    San Raffaele - Telethon Institute for Gene Therapy, Italy

    Group Leader at the San Raffaele - Telethon Institute for Gene Therapy (SR-Tiget) and Professor at the Vita-Salute San Raffaele University in Milano, Italy. Co-founder of Chroma Medicine.

    Google Scholar ORCIID Lab Webpage Company Webpage

  • Anna Cereseto

    Anna Cereseto

    University of Trento, Italy

    Professor. and Vice-Director of Department at University of Trento, and Co-Founder of Alia Therapeutics.

    Google Scholar ORCIID LinkedIn Lab Webpage

  • Avencia Sanchez-Mejias

    Avencia Sanchez-Mejias

    INTEGRA Therapeutics

    CEO and Co-founder at INTEGRA Therapeutics.

    Google Scholar ORCIID LinkedIn Company Webpage

  • Ayal Hendal

    Ayal Hendal

    Bar-Ilan University, Israel

    Principal Investigator and Group leader at Bar-Ilan University, Israel.

    Google Scholar ORCIID LinkedIn Lab Webpage

  • Ben Kleinstiver

    Ben Kleinstiver

    Harvard Medical School and Massachusetts General Hospital

    Assistant Professor at the Center for Genomic Medicine, Harvard Medical School. MGH Research Scholar at Massachusetts General Hospital.

    Google Scholar ORCIID LinkedIn Lab Webpage

  • Bernhard Schmierer

    Bernhard Schmierer

    Karolinska Institutet, Sweden

    Head of the CRISPR Functional Genomics unit at the SciLifeLab and Karolinska Institutet in Stockholm, Sweden.

    Google Scholar ORCIID LinkedIn Lab Webpage

  • Christian Groendahl

    Christian Groendahl

    SNIPR Biome

    CEO and Co-founder at SNIPR Biome.

    LinkedIn Company Webpage

  • Hao Wu

    Hao Wu

    Full Circles Therapeutics/Stellate DNA, USA

    Co-Founder and CSO of Full Circles Therapeutics, as well as the Director of Stellate DNA.

    LinkedIn Company Webpage

  • Jan Gorodkin

    Jan Gorodkin

    University of Copenhagen, Denmark

    Prof. and Group leader at University of Copenhagen, Denmark.

    Google Scholar ORCIID LinkedIn Lab Webpage

  • Jan Nelis

    Jan Nelis

    Ariya Bio

    Co-Founder and Project Lead at Ariya Bio.

    LinkedIn Company Webpage

  • Karim Benabdellah

    Karim Benabdellah

    Fundación Pública Andaluza Progreso y Salud, Spain.

    Senior Scientist at the GENyO. Pfizer-University of Granada-Junta de Andalucia Center for Genomics and Oncological Research in Granada, Spain.

    LinkedIn Google Scholar ORCIID Lab Webpage

  • Karina Thorn

    Karina Thorn

    Novo Nordisk

    Corporate Vice President, PhD, RNA and Gene Therapies, Global Research Technologies at Novo Nordisk.

    LinkedIn Company Website

  • Kevin Holden

    Kevin Holden


    Head of Science & Applied Research at Synthego.

    ORCIID Linkedin Company Webpage

  • Laura Sepp-Lorenzino

    Laura Sepp-Lorenzino

    Intellia Therapeutics

    Executive Vice President and Chief Scientific Officer at Intellia Therapeutics.

    Google Scholar LinkedIn Company Webpage

  • Manuel Kaulich

    Manuel Kaulich

    Goethe University Frankfurt, Germany

    Prof. at Goethe University Frankfurt, Germany and CSO at Vivlion.

    Google Scholar ORCIID LinkedIn Lab Webpage Company Webpage

  • Marcello Maresca

    Marcello Maresca

    AstraZeneca AB

    Senior Director of Genome Engineering Team at AstraZeneca.

    ORCIID LinkedIn Company Webpage

  • Marianne Carlon

    Marianne Carlon

    Catholic University (KU) Leuven, Belgium

    Ass. Prof. at the Laboratory of Respiratory Diseases and Thoracic Surgery (BREATHE) and the Center for Molecular Medicine of the KU Leuven Faculty of Medicine.

    Google Scholar ORCIID LinkedIn BREATHE Webpage KU Leuven Webpage

  • Paula Rio

    Paula Rio

    CIEMAT/CIBERER/IIS-FJD, Universidad Autónoma de Madrid

    Head of the Bone Marrow Failure Unit at CIEMAT/CIBERER/IIS-FJD at the Universidad Autónoma in Madrid.

    Google Scholar ORCIID LinkedIn Unit Webpage

  • Pia Johansson

    Pia Johansson

    Lund University, Sweden

    Scientific Coordinator of the Cell and Gene Therapy Core at Lund University.

    Google Scholar ORCIID LinkedIn Lab Webpage

  • Rasmus O. Bak

    Rasmus O. Bak

    Aarhus University, Denmark

    Ass. Prof. at the Department of Biomedicine at Aahrus University and Co-Founder of UNIKUM Therapeutics.

    Google Scholar ORCIID LinkedIn Lab Webpage

  • Samantha Maragh

    Samantha Maragh

    National Institute of Standards & Technology, USA

    Leader of the Gene Editing Program at the National Institute of Standards & Technology.

  • Simon Reed

    Simon Reed

    Broken String Biosciences

    Co-Founder and CSO at Broken String Biosciences.

    LinkedIn Company Webpage

  • Stefano Stella

    Stefano Stella


    Vice-President of Gene Editing at Ensoma, Founder and Chief Technology Officer at Twelve Bio, Ass. Prof. at the Novo Nordisk Foundation Center for Protein Research, University of Copenhagen, Denmark.

    ORCIID LinkedIn Company Webpage

  • Toni Cathomen

    Toni Cathomen

    University of Freiburg, Germany

    Prof. and Director at the Institute for Transfusion Medicine and Gene Therapy, University of Freiburg.

    Google Scholar ORCIID LinkedIn Institute Webpage

  • Waseem Qasim

    Waseem Qasim

    UCL Great Ormond Street Institute of Child Health, UK

    Consultant in Paediatric Immunology and a Prof. of Cell & Gene Therapy at the Infection, Immunity & Inflammation Department at University College London (UCL) Great Ormond Street (GOS) Institute of Child Health

    Google Scholar ORCIID LinkedIn Lab Webpage

  • Xavier Duportet

    Xavier Duportet

    Eligo Bioscinece

    CEO and Co-founder at Eligo Bioscience.

    Google Scholar LinkedIn Company Webpage

  • Yonglun Luo

    Yonglun Luo

    Aarhus University, Denmark

    Prof. of Gene and Stem Cell Technology at Aarhus University, Denmark and Executive Director at the Lars Bolund Institute of Regenerative Medicine, China.

    Google Scholar ORCIID LinkedIn Lab Webpage

Scientific Committee

· Marcello Maresca, Senior Director, Genome Engineering Team, AstraZeneca, Sweden
· Toni Cathomen, Prof. and Director of the Institute for Transfusion Medicine and Gene Therapy, University of Freiburg, Germany
· Alessia Cavazza, Ass. Prof., Group Leader, University College London Greater Ormond Street Institute of Child Health, England
· Anna Cereseto, Prof. and Vice-Director, Centre for Integrative Biology (CIBIO), University of Trento, Italy at University of Trento, Italy
· Karen O´Hanlon Cohrt, Chief Editor CMN

Organising Committee

· Karen O´Hanlon Cohrt, Chief Editor, CRISPR Medicine News
· Gorm Palmgren, Science Writer and Editor, CRISPR Medicine News
· Jens-Ole Bock, Founder, CRISPR Medicine News
· Antonio Carusillo, Science Writer, CRISPR Medicine News
· Manel Lladó, Science Writer, CRISPR Medicine News

Attendees (confirmed) - Companies and Organisations

  • Ariya Bio
  • AstraZeneca
  • Bar-Ilan, Israel
  • Bayer
  • Broken String Biosciences
  • Cascure
  • Cellectis
  • Chroma Medicine
  • Eligo Bioscience
  • Full Circles Therapeutics
  • Goethe University, Frankfurt
  • Harvard Medical School
  • Integra Therapeutics
  • Intellia Therapeutics
  • Karolinska Institute, Sweden
  • Lund University, Sweden
  • National Institute of Standards & Technology (NIST), US
  • Novo Nordisk
  • San Raffaele - Telethon Institute for Gene Therapy (SR-Tiget), Italy
  • SNIPR Biome
  • UCL, England
  • Uni Klinik Freiburg, Germany
  • University of Aarhus, Denmark
  • Universidad Autónoma de Madrid, Spain
  • University of Copenhagen, Denmark
  • University of Trento, Italy
  • Verve Therapeutics
  • Vita-Salute San Raffaele University, Italy

Attendees (confimed) - Investors

  • Lundbeck Foundation
  • Eir Ventures

List of reviewers

Coming soon!


Copenhagen, Denmark

Registration period

August 1, 2023 - 00:00 until April 21, 2024 - 18:00

Submission period

August 1, 2023 - 12:00 until January 24, 2024 - 18:00

Contact us

If you have any questions, please contact info@crisprmedicineconference.com .